LIVZON PHARMA (01513.HK): Wandai Tang Granules win approval
- The formula comes from Fu Qingzhu Nü Ke by Fu Shan and is listed in the first batch of the Catalogue of Ancient Classic Famous Formulas.
- The product is in granule form, with each bag equivalent to 22.13 g of crude drugs, and Sichuan Guangda is both the marketing authorisation holder and the manufacturer.
NewTimeSpace News: On 27 October 2026, Livzon Pharmaceutical Group Inc. (stock code: 01513.HK) said its subsidiary Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for Wandai Tang Granules, a Class 3.1 traditional Chinese medicine. the approval is valid until 25 October 2031.
The formula comes from Fu Qingzhu Nü Ke by Fu Shan of the Qing dynasty and is on the National Administration of Traditional Chinese Medicine's first list of ancient classic formulas. It is indicated to invigorate the spleen, soothe the liver, resolve dampness and stop leukorrhea. The product is the first of its kind approved in China and the Company's second Class 3.1 new drug. Cumulative R&D spending was RMB 4.4746 million, and the Company expects no material impact on near-term results.
- LIVZON PHARMA (01513.HK): Tiange Dingxuan wins trial approval
- LIVZON PHARMA (01513.HK): Leuprorelin 3-Month Formulation Approved
- LIVZON PHARMA (01513.HK): Proposes Appointment of Zhu Linlin as Non-Executive Director of the Twelfth Board
- LIVZON PHARMA (01513.HK): Zhu Baoguo resigns as Chairman on retirement; President Liu Daping appointed
- LIVZON PHARMA (01513.HK): Lecankitug injection approved for marketing; first domestic IL-17A/F dual-target biologic in China
